Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Vladimír Maisnar"'
Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone
Publikováno v:
Acta Medica, Vol 59, Iss 2, Pp 50-53 (2016)
Background: A combination of low-dose thalidomide and corticosteroids is a treatment option for anaemic patients with primary myelofibrosis (PMF) who are not eligible for allogeneic hematopoietic stem cell transplantation. Methods: We describe the ou
Externí odkaz:
https://doaj.org/article/b85dc71fb2934dd19688ce05d2d099b4
Autor:
Jakub Radocha, Vladimír Maisnar, Alžběta Zavřelová, Melanie Cermanová, Miriam Lánská, Miloslav Kmoníček, Ladislav Jebavý, Milan Bláha, Jaroslav Malý, Pavel Žák
Publikováno v:
Acta Medica, Vol 56, Iss 1, Pp 9-13 (2013)
Introduction: Autologous stem cell transplantation (ASCT) became standard of care for patients with multiple myeloma (MM) under the age of 65 years. We routinely perform ASCT for newly diagnosed MM since 1996 in our department. Patients and methods:
Externí odkaz:
https://doaj.org/article/2cd01e2edbe046fd8882bf5db20d0974
Publikováno v:
Acta Medica, Vol 49, Iss 2, Pp 119-121 (2006)
We carried out a retrospective analysis on a series of 1743 plasma donors during the period from January 1999 to February 2004 to determine the frequency of monoclonal gammopathies occurrence. In the whole group, we observed 0.68% occurence and in th
Externí odkaz:
https://doaj.org/article/16ff9709078b47ccaf440a0a1aa5c699
Autor:
Ladislav Chrobák, Pavel Žák, Karel Podzimek, Lenka Plíšková, Jaroslava Foglová, Vladimír Maisnar, Petr Dulíček, Karel Dědič
Publikováno v:
Acta Medica, Vol 40, Iss 2, Pp 41-45 (1997)
We treated 19 patients with hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine. 15 patients followed up at least 6 months were evaluated. The follow up period varied between 6 months and 37 months (median, 19 months). 8 patients were previously tr
Externí odkaz:
https://doaj.org/article/9fc575e5ef91490b9154ab12c25dc981
Autor:
Viera SANDECKA, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Jakub RADOCHA, Tomáš JELÍNEK, Petr PAVLÍČEK, Alexandra JUNGOVÁ, Petr KESSLER, Marek WRÓBEL, Martin ŠTORK, Jan ŠTRAUB, Tomáš PIKA, Lenka ČÁPKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimír MAISNAR, Roman HÁJEK
Publikováno v:
Neoplasma. 69(6)
We assessed the outcomes of pomalidomide and dexamethasone treatment in relapsed/refractory multiple myeloma (RRMM) patients with ≥1 prior line of therapy. We analyzed the data of all RRMM patients treated with pomalidomide and dexamethasone at nin
Autor:
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Spicka
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to M
Externí odkaz:
https://doaj.org/article/ac4fa0e66df54bf9a47e4350692f9954
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Enrique M. Ocio, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, María-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul G. Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Luděk Pour
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Melphalan flufenamide (melflufen), a first-in-class, alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen
Externí odkaz:
https://doaj.org/article/2fc23bce08c444d98389254c7b7873ab
Autor:
Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik H. Schjesvold, Ivan Spicka, Vladimir Maisnar, Artur Jurczyszyn, Zhanet Grudeva-Popova, Roman Hájek, Ganna Usenko, Marcus Thuresson, Stefan Norin, Sara Jarefors, Nicolaas A. Bakker, Paul G. Richardson, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of the
Externí odkaz:
https://doaj.org/article/0bf9f72785bc4d0cad26c30e6349239e
Autor:
Maria Gavriatopoulou, Andrew Spencer, Daniel Coriu, Fernando Escalante Barrigón, Roman Hájek, Fernanda Seguro, Norma C. Gutiérrez, Sandra Basic Kinda, Massimo Offidani, Dorotea Beatriz Eugenia Fantl, Rosane Bittencourt, Anna Lysén, Vladimir Maisnar, Elham Askari, Joaquín Martinez-Lopez, Olivia Hughes, Rebekah Taylor, Kristin Lehn, Roby Joehanes, Jeremy Ross, Carlos Hader
Publikováno v:
HemaSphere, Vol 7, p e9381810 (2023)
Externí odkaz:
https://doaj.org/article/b5ab678bac0d4bd9be6641ea15db9cae